🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Second Cancer

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents NCT05442216Phase 27 sites📍 Miami📍 Orlando📍 Buffalo Joshua Zeidner · Tests: Tagraxofusp, Azacitidine, Venetoclax A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer NCT05375591n/a2 sites📍 London📍 London Royal Marsden NHS Foundation Trust · Tests: Non-Interventional Study A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse NCT06643585Phase 31 site📍 Ulm Prof. Wolfgang Janni · Tests: Trastuzumab-Deruxtecan, Physicians Choice (PhC). Novel MRI Techniques on Evaluation of Lymphedema NCT05804643n/a1 site📍 Taipei National Taiwan University Hospital · Tests: Diffusion magnetic resonance imaging Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India NCT07209917NA4 sites📍 Bangalore📍 Bangalore📍 Bangalore University of California, Irvine · Tests: SAKHI HPV Intervention, Enhanced Standard of Care (SOC+) A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy NCT07378969n/a4 sites📍 Kurume📍 Osaka📍 Suita Novartis Pharmaceuticals A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer NCT06962137Phase 26 sites📍 Antwerp📍 Brussels📍 Brussels Universitaire Ziekenhuizen KU Leuven · Tests: zolbetuximab, Retrospective cohort, no intervention Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer NCT04745390NA1 site📍 London London Health Sciences Centre Research Institute OR Lawson … · Tests: Radiation therapy Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma NCT06676527n/a1 site📍 Nanjing Jinling Hospital, China · Tests: Follow-up study of the treated cohort Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC NCT06876844Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: combination of Surufatinib and Envolizumab Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma NCT03886311Phase 21 site📍 Santa Monica Sarcoma Oncology Research Center, LLC · Tests: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin … Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer NCT04592211Phase 1, Phase 21 site📍 Seoul Yonsei University · Tests: olaparib+pembrolizumab+paclitaxel High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors NCT06418789Phase 21 site📍 Saint Petersburg N.N. Petrov National Medical Research Center of Oncology · Tests: High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles ) Second-line Immunotherapy for ES-SCLC NCT06853678NA1 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Adebrelimab, Selinexor, Nab-paclitaxel Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer NCT06490159n/a1 site📍 Kurashiki City of Hope Medical Center · Tests: Paclitaxel Parathyroid Tumor Clonal Status NCT05997810n/a1 site📍 St Louis Washington University School of Medicine Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial NCT07106034Phase 21 site📍 Shanghai Shanghai Pudong Hospital · Tests: Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas NCT05681195Phase 21 site📍 Miami Baptist Health South Florida · Tests: Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT) A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC NCT03303495Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Bevacizumab, CPT-11, 5-FU Bolus, 5-FU Infusion, l-LV (dl-LV) Carboplatin or Olaparib for BRcA Deficient Prostate Cancer NCT04038502Phase 218 sites📍 West Los Angeles📍 Aurora📍 Washington D.C. VA Office of Research and Development · Tests: Carboplatin, Olaparib Secondary Care Colorectal Cancer Pathway Review NCT07430527n/a2 sites📍 Edinburgh📍 Edinburgh University of Edinburgh · Tests: Faecal Immunohistochemical test Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136Phase 21 site📍 Shanghai Fudan University · Tests: Vebrekotuzumab, PD-1 antibody Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer NCT06184698Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: liposomal irinotecan, 5-FU, LV, Bevacizumab Adaptive Radiation for Abdominopelvic Metastases NCT05880667Phase 11 site📍 Philadelphia Fox Chase Cancer Center · Tests: Adaptive Stereotactic Body Radiation A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites📍 Birmingham📍 Stockton📍 Torrance Novartis Pharmaceuticals · Tests: TKIs Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab NCT06540326Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: irinotecan liposome (II), fluorouracil, cetuximab, bevacizumab, Capecitabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy